Our lead product is a zinc-chlorite–based surgical irrigant licensed for commercialization with positive FDA feedback. It has demonstrated 800–21,000× greater efficacy than leading antimicrobial irrigants in lab testing and is expected to launch in 2026 following 510(k) clearance.

We have developed advanced antimicrobial wound dressings that eliminate biofilms, help prevent infections and support healing in both acute and chronic wounds. These formulations are non-cytotoxic, non-antibiotic, kill even antibiotic resistant organisms, and safe for use on open wounds — a major unmet need in the $8B wound care market.

Our antimicrobial packing materials target deep and tunneling wounds, including trauma, surgical sites and abscesses. By delivering sustained zinc-chlorite activity, these materials help prevent infection recurrence and biofilm regrowth in hard-to-reach spaces.